An observational study in COVID-19 and Cancer, sponsored by Duke University. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-06.
Sponsored by Duke University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in COVID-19 by Duke University — 4 open to participants now, 5 under way, none of them phase 3. COVID-19 · Duke University.
Among the 39 studies in COVID-19 by Duke University, this one is the 8th largest by planned enrollment of the 21 observational ones that give a count, is one of 14 that started in 2020, is one of 21 observational ones, and was the 8th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →4 of the 39 studies in COVID-19 by Duke University are open now, in 2 countries. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18+
Duke University · Sites in United States, Canada
Ages 0–20 · Healthy volunteers
Duke University · Sites in United States
Ages 2+ · Healthy volunteers
By country, each count listing its studies:
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 4 2
First in 2020; this study’s year is marked. 14 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 268 across 3,209 observational studies indexed under COVID-19.
Median enrollment 49 across the 18 interventional studies, 338 across the 21 observational. Of the 29 that completed or were terminated, 13 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
Duke University is the lead sponsor of 2,064 studies on the registry; 271 are open to participants now.
Of its 204 completed or terminated interventional studies of FDA-regulated products, 170 (83%) have results posted.
4 of the studies in COVID-19 by Duke University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
| NCT05218083Duke UniversityREmotely Monitored, Mobile Health Supported Multidomain Rehabilitation Program With High Intensity Interval Training for COVID-19 | 2027-01-01 |
| NCT04357574Duke UniversityAssessing the System for High-Intensity Evaluation During Radiotherapy During Changes in Response to COVID-19 | 2027-04 |
| NCT04368234Duke UniversityDuke COVID-19 Shared Data and Specimen Repository | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 39 studies in COVID-19 by Duke University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this research study is to assess Radiation Oncology healthcare providers (i.e. faculty, residents and advanced practice providers (APPs) implementation and perception of telehealth for on treatment patients in lieu of in person on treatment visits during standard of care radiotherapy during COVID-19.
A secondary aim will be to evaluate the rates of acute care during COVID-19 with telehealth in comparison to the rates during our prior Quality Improvement (QI) project (NCT04277650), considering the risk prediction based on our previously developed ML algorithm. Patient risk during this period will be assessed by the ML algorithm and actual rates of Emergency Department visits and hospitalizations (acute encounters) will be compared to the results of our prior QI project. These data will be used to discern how actual rates of acute care compare to providers' expectations both with and without telehealth implementation. Reasons for acute encounters and associated healthcare costs compared to patients undergoing standard of care assessments in NCT04277650 will be assessed to determine the percentage that are COVID-19 related. Basic demographic, disease, location of acute care, form of clinical assessments (video, in-person, telephone, etc.), and treatment information regarding the patients will also be captured following the completion of the research project for assessment.
These endpoints will establish how our current COVID-19-based precautions impact treatment-related outcomes in patient care.
Patients undergoing radiation therapy in the Department of Radiation Oncology at Duke Cancer Center during the COVID-19 outbreak
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Faculty physicians, residents and advanced practice providers in the Radiation Oncology Department in Duke University Health System (DUHS)
Other: Telehealth
patients have virtual visits with Radiation Oncology providers in lieu of in person clinic visits as a necessary response to COVID-19
Radiation Oncology providers perception of of telehealth for on treatment patients in lieu of in person on treatment visits during COVID-19
survey assessment scored as strongly agree (positive perception) through strongly disagree (negative perception)
Time frame: 12 months
Number of missed telehealth clinical evaluation visits during COVID-19
Time frame: 12 months
Number of unplanned emergency department visits or hospital admissions during COVID-19
Time frame: 12 months
Number of acute care visits with listed reason as anemia, nutrition (including dehydration), diarrhea, emesis, infectious (including fever, pneumonia, and sepsis), nausea, neutropenia, pain category during COVID-19
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2020 (actual). Primary completion is estimated for Apr 2027, 84 months after the start.
Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 84 months is above that.
Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.